Rare Diseases: Drugs
Commons · Question 69240 · Tabled 21 Jul 2025 · Department of Health and Social Care · Official record
Answered 1 Sep 2025
Question
Asked by Jim Shannon
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the (a) pricing and (b) reimbursement system for multi-indication medicines is adequate for patients with (i) rare and (ii) ultra-rare conditions.
Answer
Answered by Karin Smyth, 1 Sep 2025
Indication-specific pricing can support access to treatments, including for rare conditions, by enabling companies to propose a specific price for smaller indications that would otherwise be commercially unviable under a uniform price.In January 2025, fol...